Dr Richard Barker
Director, CASMI. Chair, South London AHSN
Dr Richard Barker is a strategic advisor, speaker and author on healthcare and life sciences. He is Director of the Centre for the Advancement of Sustainable Medical Innovation, a major European initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances more rapidly and affordably to patients.
Dr Ernie Harpur
Toxicologist, University of Newcastle
Following periods of doctoral and post-doctoral research in toxicology, Ernie spent 13 years in academia where his research interests centered on investigations of mechanisms of toxicity. Ernie subsequently worked for 21 years in Drug Safety Assessment in pharmaceutical industry based in Europe and the USA, for the last 9 years as Global Head of Scientific Affairs and Regulatory Standards.
Professor Frank Bonner
Professor Frank Bonner was appointed Chief Executive of Stem Cells for Safer Medicines in July, 2009 and led a successful funding effort with the private and public sectors which provided support for the current research campaign.
Dr Mark Bale
Interim Director of Health Science and Bioethics, DoH
Dr Mark Bale PhD is Interim Director of Health Science and Bioethics and Head of Profession for Scientists in the Department of Health. His Division has responsibility for genetics and genomics, stem cells, emerging science, tissue, embryology and assisted conception donation (including HFEA, HTA and NHSBT sponsorship), sexual health, screening and sponsorship of MHRA.
Head of Science and Technology Team, BPE
Robert Bryan has been working with organisations and individuals operating in science, technology, engineering and healthcare for 15 years. As the Company Secretary to SC4SM as well as being the legal adviser to such bodies as the Royal Society, the Royal Academy of Engineering and the Physiological Society, Rob is working at the heart of UK science, technology and engineering.
Dr Paul Duffy
Senior Project Director, AstraZeneca
Dr Paul Duffy is Lead Toxicologist and member of the leadership team in the New Opportunities Innovative medicines Group and on the leadership team of AstraZeneca’s Global Safety Assessment function he is also the Toxicology project Lead on a number of late stage potential new medicines within AstraZeneca.
Professor Tim Hammond
Consultant, pharmaceutical drug Discovery and Development
Professor Tim Hammond is a consultant with 35 years experience in pharmaceutical drug Discovery and Development. He was previously the Vice President of Safety Assessment in the UK for AstraZeneca.
Copyright © 2019 | SC4SM